1 / 20

4 TH MEETING OF TECHNOLOGICAL NETWORK ON HIV/AIDS

4 TH MEETING OF TECHNOLOGICAL NETWORK ON HIV/AIDS. Rio de Janeiro, Brazil Dec 10-14, 2007. Representatives from Thailand. 1. ดร . บุญฑริกา บุญญภิวัฒน์ กรมวิทยาศาสตร์การแพทย์ 2. ดร . วลัยลักษณ์ เมธาภัทร กรมวิทยาศาสตร์การแพทย์ 3. ดร . รัชนีกร เจวประเสริฐพันธุ์ องค์การเภสัชกรรม

petula
Download Presentation

4 TH MEETING OF TECHNOLOGICAL NETWORK ON HIV/AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 4TH MEETING OF TECHNOLOGICAL NETWORK ON HIV/AIDS Rio de Janeiro, Brazil Dec 10-14, 2007

  2. Representatives from Thailand • 1. ดร. บุญฑริกา บุญญภิวัฒน์ กรมวิทยาศาสตร์การแพทย์ • 2. ดร. วลัยลักษณ์ เมธาภัทรกรมวิทยาศาสตร์การแพทย์ • 3. ดร. รัชนีกร เจวประเสริฐพันธุ์องค์การเภสัชกรรม • 4. ดร. อรศิริ ศรีคุณ องค์การเภสัชกรรม

  3. 8 countries in the network China, Cuba, Russia, Thailand, Ukraine, Argentina, Brazil andNigeria

  4. The main objectives of the network • To make HIV drugs accessible and affordable for all. • To develop and produce HIV tests, CD4 cell count tests, viral load tests, and genotyping.

  5. Roles and Activities of the network “ To establish potential partnerships in order to encourage/facilitate information sharing and technology transfer for API production, ARV formulation and laboratory infrastructure” 3 Meetings held; 1st in Brazil, January 2005, 2nd in Shanghai, August 2005and 3rd in Cuba, June 2006

  6. 2 Workshops Biological processes ARV formulation and API production • Genotype samples-Resistance and Surveillance • Quality control-Serology (Diagnostic Kits ) • Quality Control-Viral load • Information sharing: strategic ARV drugs, infrastructure • Problem discussion: Technical bottle neck • Drafting proposals

  7. Strategic ARV drugs • Tenofovir DF • Emtricitabine Lamivudine

  8. Strategic ARV drugs (continued) • Efavirenz • Ritonavir/Lopinavir

  9. Strategic ARV drugs (continued) • Atazanavir • Abacavir

  10. ARV drugs under patents

  11. Cooperation between country members • Cooperation project on formulation development • Analytical methodology • Stability studies • Physical and chemical test, bioequivalent studies • Technical consultancy

  12. Focused ARV drugs • Tenofovir • Atazanavir • Abacavir • Lopinavir/r (Heat stable) for both adult and pediatric formulation • Ritonavir (Heat stable) • Fixed dose combination (i.e. Lamivudine+Efavirenz+Tenofovir, Emtricitabine+Tenofovir+Efavirenz and Lamivudine+ Zidovudine, Lamivudine+Zidovudine+Nevirapine for Pediatric)

  13. Action plan

  14. The Institute of Pharmaceutical Technology Farmanguinhos • The Replace Laboratory of the Brazilian Ministry of Health • GMP(Certificate by National agency) • ARV, Antibiotic, Analgesic, Diabetics, Cardiovascular, Respiratory, Antimalaria medicines • DDI, Stavudine, Lamivudine, Nevirapine and Lamivudine/AZT • 65% ofBudget fromBrazil Government forSecond line drug (Lopinavir/r, Efavirenz and Saquinavir) • Technology transfer (i.eProduction of ARV, ARV Plant with Nigeria andMozambique

  15. Next Meeting Thailand 2008

  16. WORK SHOP

  17. The Institute of Pharmaceutical Technology Farmanguinhos

  18. Christ of Redeemer Sugar Loaf

More Related